Li Zhenzuo, Wang Baolan, Bai Dongfang, Zhang Li
Department of Endocrinology, The Fourth People's Hospital of Jinan, Jinan, China.
Department of Endocrinology, Taian City Central Hospital, Taian, China.
Food Nutr Res. 2024 Aug 20;68. doi: 10.29219/fnr.v68.10749. eCollection 2024.
The global prevalence of diabetic heart complication has been on the increase, and some of the drugs that are currently used to treat diabetes mellitus (DM) have not been able to mitigate this complication.
This study determines the effect of Brazil nut () and metformin on diabetic cardiomyopathy (DCM) in fructose/streptozotocin (STZ)-induced type 2 diabetic rats and also characterizes using Gas Chromatography Mass Spectrophotometry and Fourier Transform Infrared the bioactive compounds in 50% aqueous ethanol extract of Brazil nut.
After inducing type 2 DM, 30 male albino Wistar rats were separated into five groups that comprised of six rats per group, and they were treated as follows: groups 1 (Control) and 2 (Diabetic control) rats received rat pellets and distilled water; group 3 (Diabetic + Brazil nut) received rat pellets and Brazil nut extract (100 mg/kg, orally) dissolved in distilled water, group 4 (Diabetic + metformin) received metformin (100 mg/kg, orally) dissolved in distilled water, while group 5 (Diabetic + Brazil nut + metformin) received oral administrations of Brazil nut (100 mg/kg) and metformin (100 mg/kg) dissolved in distilled water. This study lasted for 6 weeks. The dose of Brazil nut used was selected from our pilot study on the minimum therapeutic dose of different concentrations of Brazil nut extract.
STZ administration induced insulin resistance, hyperglycemia, loss of weight, dyslipidemia, oxidative stress, inflammation, apoptosis, alteration of mammalian target of rapamycin, mitogen-activated protein kinase, heart function markers (creatine kinase MB, lactate dehydrogenase, and aspartate amino transaminase), and heart histology of the diabetic control, which was ameliorated after treatment with Brazil nut and metformin, but their combined treatment was better than the single treatments.
This study shows that Brazil nut contains several bioactive compounds that support its biological properties as well as its candidature as a complementary therapy to metformin in mitigating cardiac complications arising from DM in rats.
糖尿病心脏并发症的全球患病率一直在上升,目前用于治疗糖尿病(DM)的一些药物未能减轻这种并发症。
本研究确定巴西坚果()和二甲双胍对果糖/链脲佐菌素(STZ)诱导的2型糖尿病大鼠糖尿病性心肌病(DCM)的影响,并使用气相色谱 - 质谱法和傅里叶变换红外光谱法对巴西坚果50%乙醇水提取物中的生物活性化合物进行表征。
诱导2型糖尿病后,将30只雄性白化Wistar大鼠分为五组,每组6只大鼠,并进行如下处理:第1组(对照组)和第2组(糖尿病对照组)大鼠接受大鼠颗粒饲料和蒸馏水;第3组(糖尿病 + 巴西坚果)接受大鼠颗粒饲料和溶于蒸馏水中的巴西坚果提取物(100 mg/kg,口服),第4组(糖尿病 + 二甲双胍)接受溶于蒸馏水中的二甲双胍(100 mg/kg,口服),而第5组(糖尿病 + 巴西坚果 + 二甲双胍)接受溶于蒸馏水中的巴西坚果(100 mg/kg)和二甲双胍(100 mg/kg)的口服给药。本研究持续6周。所用巴西坚果的剂量是从我们关于不同浓度巴西坚果提取物最小治疗剂量的初步研究中选择的。
给予STZ诱导了胰岛素抵抗、高血糖、体重减轻、血脂异常、氧化应激、炎症、细胞凋亡、雷帕霉素哺乳动物靶点、丝裂原活化蛋白激酶、心脏功能标志物(肌酸激酶MB、乳酸脱氢酶和天冬氨酸氨基转氨酶)的改变以及糖尿病对照组的心脏组织学变化,用巴西坚果和二甲双胍治疗后这些变化得到改善,但联合治疗比单一治疗效果更好。
本研究表明,巴西坚果含有几种生物活性化合物,支持其生物学特性以及作为二甲双胍的辅助疗法减轻大鼠糖尿病引起的心脏并发症的候选资格。